CAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings

Zeljko Todorovic; Dusan Todorovic; Vladimir Markovic; Nevena Ladjevac; Natasa Zdravkovic; Predrag Djurdjevic; Nebojsa Arsenijevic; Marija Milovanovic; Aleksandar Arsenijevic; Jelena Milovanovic

doi:10.3390/curroncol29050293

Current Oncology (May 2022)

CAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings

Zeljko Todorovic,
Dusan Todorovic,
Vladimir Markovic,
Nevena Ladjevac,
Natasa Zdravkovic,
Predrag Djurdjevic,
Nebojsa Arsenijevic,
Marija Milovanovic,
Aleksandar Arsenijevic,
Jelena Milovanovic

Affiliations

Zeljko Todorovic: Department of Internal Medicine, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia
Dusan Todorovic: Department of Ophthalmology, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia
Vladimir Markovic: Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia
Nevena Ladjevac: Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia
Natasa Zdravkovic: Department of Internal Medicine, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia
Predrag Djurdjevic: Department of Internal Medicine, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia
Nebojsa Arsenijevic: Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia
Marija Milovanovic: Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia
Aleksandar Arsenijevic: Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia
Jelena Milovanovic: Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia

DOI: https://doi.org/10.3390/curroncol29050293
Journal volume & issue: Vol. 29, no. 5
pp. 3647 – 3657

Abstract

Read online

Chimeric antigen receptor T (CAR T) cell therapy achieved remarkable success in B-cell leukemia and lymphoma which led to its incorporation in treatment protocols for these diseases. CAR T cell therapy for chronic lymphocytic leukemia (CLL) patients showed less success compared to other malignant tumors. In this review, we discuss the published results regarding CAR T cell therapy of CLL, possible mechanisms of failures and expected developments.

Published in Current Oncology

ISSN: 1198-0052 (Print); 1718-7729 (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.mdpi.com/journal/curroncol

About the journal

Abstract

Keywords